Pluri is a bio-technology company focused on the field of regenerative medicine. Co. is developing placenta-based cell therapy product candidates for the treatment of muscle trauma, hematological disorders, radiation damage and inflammation. Co.'s operations are focused on the research, development and manufacturing of cells, conducting clinical studies and the business development of cell therapeutics and cell based technologies, such as its collaboration with Tnuva Food Industries – Agricultural Cooperative in Israel Ltd.,through its fully owned subsidiary, Tnuva Food-Tech Incubator (2019), Limited Partnership, to use Co.'s technology to establish a cultured food platform. The PLUR stock yearly return is shown above.
The yearly return on the PLUR stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2017 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the PLUR annual return calculation with any dividends reinvested as applicable (on ex-dates).
|